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Abbreviations 
ACE   angiotensin converting enzyme  
ACE 2   angiotensin converting enzyme 2  
AM   adrenomedullin 
APJ   angiotensin-like putative receptor  
Ang II   angiotensin II 
AT1-R   angiotensin II type 1 receptor 
AP   action potential 
cAMP    cyclic adenosine monophosphate   
CGRP    calcitonin gene-related peptide  
CLR   calcitonin receptor-like receptor 
DT   developed tension 
EGFR   epidermal growth factor receptor 
ERK   extracellular signal-regulated kinase 
GPCR    G-protein coupled receptors  
MAPK   mitogen-activated protein kinase 
MEK   MAPK kinase 
p38-MAPK  p38 mitogen-activated protein kinase 
NCX    sarcolemmal Na+/Ca2+ exchanger  
NHE    Na+/H+ exchanger  
NHE-1    Na+/H+ exchanger isoform 1 
PAMP    proadrenomedullin N-terminal 20-peptide  
PKA    protein kinase A  
PKC    protein kinase C  
PLC   phospholipase C 
PLB vs PLN  phospholamban  
RAS    renin-angiotensin system 
RAMPs  receptor-activity modifying proteins  
RyR    ryanodine receptors  
SR    sarcoplasmic reticulum  
SERCA    SR Ca2+ -ATPase  
TnC    troponin C  
TnI   troponin I 
TnT    troponin T  
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1. Introduction  
Heart failure is a serious condition, with a mortality rate greater than 50% 
over 5 years in severe cases. Since heart failure is a complex syndrome the 
therapeutic approaches are multiple, including general measures, pharmacological 
therapy, mechanical devices and surgical intervention (Hunt et al., 2005). The 
significant improvement of heart failure has been achieved by combination therapy 
with regard to morbidity and mortality rate however, the increasing numbers and 
daily doses of drugs bare the risk of potential drug interactions and more serious 
complications (Kappert et al., 2008). At present, the only cure for severe heart failure 
has a heart transplantation, which is limited by the small number of organs. Since 
heart failure is the fastest growing incidence  within cardiovascular disease and is 
associated with substantial economic costs it indicates an extensive research 
investigating novel therapeutic strategies (Cohn et al., 2000). 
The complex clinical syndrome of heart failure is characterised by circulatory 
congestion and progressive cardiac contractile dysfunction. This is accompanied by 
molecular alterations that cause remodeling of the heart, which is a self 
perpetuating pathological process, and a deterioration of failing heart (Cohn et al., 
2000). A deeper insight into the pathophysiologic mechanisms highlight the role of 
various neurohormonal mechanisms and the antagonism of this system have 
beneficial effect on progression of heart failure (Hunt et al., 2005). 
However, as the contractility of the heart is compromised, a desirable therapy 
would involve improvement of efficiency of the contraction-relaxation cycle, but for 
the time being no effective, safe, chronic positive inotropic and lusitropic therapy 
exists for the treatment of systolic and diastolic dysfunction in heart failure. 
Regulation of myocardial contractility by endogenous peptides is important in 
physiological and pathophysiological conditions and may be a crucial therapeutic 
target in the treatment of heart failure (Brutsaert, 2003). Potent positive inotropic 
agents apelin (Brutsaert, 2003; Szokodi et al., 2002) and andrenomedullin (Szokodi et 
al., 1996) act in autocrine/paracrine manner and have demonstrated 
cardioprotective effects (Hamid and Baxter, 2006; Jia et al., 2006; Kleinz and Baxter, 
2008). Although, numerous experimental data prove the efficacy of these peptides 
the underlying molecular mechanisms are only partially understood. 
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1.1. Regulation of Cardiac Contractile Function 
Contractility is defined as the intrinsic ability of the cardiac muscle fibre to 
contract at a given fibre length. The degree of contraction is influenced by different 
degrees of binding between myofilaments which depends on concentration of 
intracellular Ca2+ and the sensitivity of myofilaments to Ca2+. The contractile function 
of the heart is regulated by a number of intrinsic and extrinsic mechanisms.  Intrinsic 
mechanisms include the Frank-Starling mechanism and the force-frequency relation. 
Extrinsic mechanisms affecting cardiac function are the autonomic nervous system, 
hormones and regulatory peptides acting in autocrine/paracrine manner. The 
complex interplay between all these factors occurre continuously via both the 
haemodynamic state and respective feedback mechanisms, and also at the level of 
single cardiomyocytes (Bers, 2002; Opie, 1995). 
1.1.1. Excitation-Contraction Coupling 
The excitation-contraction coupling includes the events which follow the 
wave of excitation and lead to contraction. Initially, the wave of depolarization 
spreads rapidly along the myocardial sarcolemma, and also into the interior of the 
cells via the invaginations of the sarcolemma, the T-tubules, opening the voltage 
dependent L-type Ca2+ channels and triggering a Ca2+ influx (Hobai and Levi, 1999). 
Ca2+ is essential in cardiac electrical activity and is the direct activator of 
myofilaments, which cause contraction (Bers, 2002).  
1.1.2. Ion Fluxes During Cardiac Cycle 
The Ca2+ entering the cell through the L-type Ca2+ channels serves as a trigger 
to release Ca2+ from the sarcoplasmic reticulum (SR) through ryanodine receptors 
(RyR) (Fabiato and Fabiato, 1979). The amplified Ca2+ release promots free Ca2+ to 
bind  to a specific site in the N-terminal domain of troponin C (TnC), resulting in a 
conformational change of the TnC molecule (Robertson et al., 1982; Solaro and 
Rarick, 1998). Cardiac troponin is a complex protein made up of three subunits: TnC, 
troponin I (TnI) and troponin T (TnT). TnC acts as the Ca2+ binding subunit, TnI 
inhibits the actin-myosin reaction and shuttles between tight binding to actin and 
tight binding to Ca2+-TnC and TnT is the tropomyosin binding subunit. As a 
consequence of the Ca2+signaling process and the conformational change in TnC, TnI 
moves from its diastolic state (tightly bound to actin) to its systolic state (tightly 
bound to TnC) (Solaro and Rarick, 1998). The interaction between TnI and TnC is 
followed by moving of the tropomyosin molecule to allow the crossbridges to attach 
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and produce force (Opie, 1995). Heads of myosins protruding from the thick filament 
then react with thin-filament actins in a reaction cycle that is powered by ATP 
(Rayment et al., 1993). 
 
 
Figure 1. The figure shows the time course of an action potential, Ca
2+
 transient and 
contraction measured in rabbit ventricular myocytes at 37 °C (Bers, 2002). 
(Abbreviations see at page 7) 
 
For relaxation Ca2+ must be removed from cytosol which occurs through SR 
Ca2+ -ATPase (SERCA), sarcolemmal Na+/Ca2+ exchanger (NCX) in the largest 
proportion and the rest through the plasma membrane calmodulin-dependent 
calcium ATPase and mitocondrial Ca2+ uniporter (Bers et al., 1998; Rayment et al., 
1993). The major regulator of SR Ca2+ transport is phospholamban (PLB) the 
endogenous inhibitor of SERCA. Phosphorylation of PLB relieves this inhibition, 
allowing faster twitch relaxation and decline of Ca2+(Koss and Kranias, 1996) 
(Maclennan and Kranias, 2003). 
The Ca2+ cycling is affected in heart failure. It was shown that Ca2+ cycling is 
reduced by approximately 50 per cent in myocytes obtained from patients with end-
stage heart failure. The intracellular Ca2+ transient demonstrates a blunted rise with 
depolarization reflecting a slower delivery of Ca2+ to the contractile apparatus 
(causing slower activation) and a slower rate of fall during repolarization (causing 
slowed relaxation) (Beuckelmann et al., 1992; Rayment et al., 1993). In consequence 
of impaired Ca2+ cycling a lot of compensatory pathways are activated. For example 
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studies have shown overexpression of NCX, which allows   greater Ca2+ influx during 
the action potential but generate intracellular Na+ overload (Pieske et al., 2002). 
Another major regulator of intracellular homeostasis is the Na+/H+ exchanger 
(NHE), which is a membrane protein that regulates ion fluxes. NHE extrudes one 
intracellular proton in exchange for one extracellular sodium thereby regulating 
intracellular pH.  Intracellular acidosis is the primary stimulus for activation of NHE 
(Karmazyn et al., 1999). However, there are many pathways that may also lead to 
NHE activation. One of them is the α1-adrenergic receptor activation  through 
phosphorylation of protein kinase C (PKC) (Wallert and Frohlich, 1992) causing 
increase in intracellular pH and Na+ concentration . The alkalinization is mainly 
responsible for the increased myofilament Ca2+ sensitivity and the rise in Na+ 
concentration contributes to the increase in Ca2+ transient via NCX. The result is a 
positive inotropy with modest negative lusitropy. Other factors can also exhibit 
stimulatory effects via phosphorylation-dependent processes. These generally 
represent various autocrine and paracrine as well as hormonal factors such as 
endothelin-1, thrombin, carbachol and angiotensin II, which probably act through 
receptor-signal transduction processes. The activation of myocardial NHE plays an 
important role in ischaemia and early reperfusion. Moreover increased activity of 
NHE was demonstrated in heart failure and the inhibition of NHE attenuated the 
functional, morphological abnormalities of the failing heart (Avkiran and Haworth, 
2003). 
1.1.3. The Frank-Starling Mechanism 
The Frank-Starling mechanism is an important intrinsic regulatory mechanism 
of myocardial contractility. It was Frank who first described this observation, namely 
the greater the preload, the greater the force generated by frog cardiac muscle 
(Katz, 2002; Knowlton and Starling, 1912; Markwalder and Starling, 1914; Patterson 
et al., 1914).  
The response of myocardium to an increased sarcomere length is biphasic (Kentish, 
1999), which means a rapid increase in active force, followed by a further increase in 
force over several minutes (Parmley and Chuck, 1973). The underlying intracellular 
mechanism is still elusive. According to the most reliable theory stretching increases 
Ca2+ affinity of TnC, since no increase in intracellular Ca2+ level is measured. Contrary 
to this, the slow phase of the Frank-Starling mechanism is associated with an 
increase of intracellular Ca2+ level via NCX operating in a reverse mode (Cingolani et 
al., 1998) . The exact mechanism of the length-dependent changes in myofilament 
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Ca2+ sensitivity is still a matter of research interest. In recent years two theories have 
emerged; one of them claims that the length-dependent changes in lattice spacing 
determine changes in Ca2+ sensitivity.   The other theory suggests that there is a 
length-sensing element (titin) in sarcomere, which can modulate actin-myosin 
interactions independent of changes in lattic spacing (Fuchs and Martyn, 2005).  
1.1.4. The Force-Frequency Relationship 
The force-frequency relationship, also known as the Treppe phenomenon was 
described by Bowditch, who showed that increasing stimulation frequency in frog 
muscle caused increased contractile force (Bowditch, 1878). There is a positive 
correlation to force-frequency relationship in non failing myocardium until the heart 
rate reaches the 170/ min value which is an important adaptive mechanism during 
stress in man. However, in the failing myocardium frequency potentiation of 
contractile force is inverse. The force-frequency relationship is explained by 
increased transsarcolemmal Ca2+ influx consequently higher intracellular Ca2+ level 
during systole (Pieske et al., 1995).  
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1.2. Extrinsic Factors Regulating Contractile Function  
1.2.1. Adrenergic Regulation of Cardiac Contractility 
Excitation-contraction coupling is affected by several extra and intracellular 
molecules, which enable to influence contractile strength. The main and most widely 
studied regulatory pathway involves the sympathetic nervous system acting through 
G-protein coupled receptors (GPCR) whose primary function is to transduce 
extracellular stimuli into intracellular signals. The effectors of the sympathetic 
nervous system such as epinephrine and norepinephrine act on cardiac myocytes via 
both β- and α-adrenergic receptors. Cardiac β-adrenergic receptors are mostly the 
β1, and β2 subtype is 20 percent of the total amount of β-adrenergic receptor 
population (Bristow et al., 1986; Steinberg, 1999). The α-adrenergic activation is also 
able to modulate cardiac contractility but its importance is less. 
  GPCRs are associated with Gs, Gi or Gq subtypes of G-proteins. The Gs 
activation (dominantly activated through β1- and β2-adrenergic receptors) enhances 
activity of adenyl cyclise producing cyclic adenosine monophosphate (cAMP). cAMP 
subsequently activates the multisubstrate enzyme protein kinase A (PKA) whose 
main targets are L-type Ca2+ channels, PLN, and TnI in cardiac myocytes (Katz, 1990; 
Walsh and Van Patten, 1994). The phosphorylation of PLN and L-type Ca2+ channels 
result in increased intracellular Ca2+ level inducing positive inotropic effect. 
Moreover, the phosphorylation of TnI decreases the sensitivity of contractile 
apparatus to Ca2+ which means increased intrinsic rate of myofibrillar relaxation 
(positive lusitropy) and so contribute to the shortening of cardiac twitch during β-
adrenergic receptor activity (Layland et al., 2004).  
In contrast to Gs, the Gi (activated through β2) pathway is responsible for 
inhibition of adenylyl cylase. Gi coupling qualitatively and quantitatively modifies the 
outcome of Gs signaling. During acute receptor stimulation, the β2-adrenergic – Gi 
coupling mediates compartmentalization of the Gs-cAMP signaling thereby negating 
the positive inotropic and lusitropic effect of β2-adrenergic activation. During 
prolonged recetor stimulation, Gi coupling activates multiple Gs-independent 
signaling pathways resulting in cardiac protective effects (Zheng et al., 2005) α-
adrenergic receptors activate Gq subtype of G-proteins. The Gq pathway involves the 
activation of phospholipase C, hydrolysis of PIP2 to diacylglicerol/IP3 and activation of 
protein kinase C (PKC). PKC represents a large gene family with up to twelwe 
isoforms, which target through phosphorylation many endeffectors  in the heart, 
including L-type Ca2+ channels, and myofilament proteins, accounting for the positive 
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inotropic actions (Kang and Walker, 2006). PKC is also capable of activating NHE 
leading to intracellular alkalinization and increased sensitivity of myofilaments to 
Ca2+ (Karmazyn et al., 1999).  
The Gq activation pathway may play an important role in many 
pathophysiological conditions, too. PKC and further downstream kinases, such as 
extracellular-regulated kinase 1/2 (ERK 1/2), p38 mitogen-activated protein kinase 
(p38-MAPK) are also important to GPCR mediated regulation of hypertrophic growth 
and to cardioprotective mechanisms underlying ischemic preconditioning (Braz et al., 
2002; Ping et al., 1999).   
1.2.2. Autocrine/Paracrine Regulation 
Not only the humoral but the autocrine/paracrine regulation is an important 
mechanism to influence contractile function.  Autocrine signaling is a form of cell 
signaling in which the target cell is the same than the signal-releasing cell, while in 
case of paracrine signaling, the target cell is near to the signal-releasing cell.  These 
locally acting mediators may be endogenous peptides, which influence different 
organ functions. For example, coronary endothelium releases endothelin-1 in 
response to elevated coronary coronary flow and endothelin-1 acting on 
cardiomyocytes results in positive inotropy (Piuhola et al., 2003). Regulation of 
myocardial contractility by endogenous peptides is important in physiological and 
pathophysiological conditions and may be a crucial therapeutic target (Brutsaert, 
2003). Apelin, andrenomedullin are part of this system with an extensive biological 
effect. 
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1.3. Emerging Role of Apelin in the Regulation of the Cardiovascular System 
Apelin is a bioactive peptide expressed in a wide variety of tissues and exerts a broad 
range of biological activity. 
1.3.1. Characterization of the Apelin System 
The gene encoding angiotensin-like putative receptor (APJ) receptor is 
localised in humans on the long arm of chromosome 11 and it was identified by 
O’Dowd in 1993. APJ receptor called angiotensin receptor-like since it shares 
sequency identity in 54% of angiotensin II type 1 receptor (AT1-R) (O'Dowd et al., 
1993). However, angiotensin II (Ang II) is unable to activate the APJ receptor (Lee et 
al., 2000) (Tatemoto et al., 1998). Apelin was found in 1998 to be an endogenous 
ligand for the APJ receptor. Initially, apelin was isolated as a 36 amino acid peptide 
from bovine stomach homogenates, that activated Chinese hamster ovary cells 
expressing the APJ receptor (Tatemoto et al., 1998).  Further investigations clarified 
that apelin secreted as 77 aminoacid and it might function as a precursor with 
limited biological activity and required further proteolysis and post-translational 
modification to result in the biologically more active form, predominantly (Pyr1) 
apelin-13 followed by apelin 12 and 16 (Kleinz and Davenport, 2005; Hosoya et al., 
2000; Lee et al., 2000; Tatemoto et al., 1998).  Apelin and APJ receptor are widely 
expressed throughout the body and have functional effects in both the central 
nervous and the cardiovascular systems.  Apelin and APJ receptor are expressed in 
the heart (O'Carroll et al., 2000; Szokodi et al., 2002) and in human coronary artery 
endothelial and coronary smooth muscle cells (Kleinz and Davenport, 2005).  There 
appears to be a lower expression in cardiomyocytes, however, there remain 
detectable levels of apelin and APJ receptor in these cells. A large density of apelin 
and its receptor was found in endocardial endothelial cells and vascular endothelial 
cells in human large conduit vessels and small arteries and veins (Kleinz and 
Davenport, 2005; Kleinz et al., 2005).  
1.3.2. Biological Effects of Apelin  
The broad distribution of apelin and its receptor throughout the body provide 
clues about the physiological functions of this novel signal-transduction system. 
Roles have been established for the apelin-APJ system in regulation of eating and 
drinking behaviour, in stress activation and as novel adipokine, but its primary effect 
seems to be in modulating vascular tone and cardiac contractility. 
The distribution of apelin and its receptor in the hypothalamus, gastric 
mucosa and fat cells has led to the suggestion, that the apelin system plays a role in 
modulating eating behaviour, nevertheless data in the literature show controversy 
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(Sunter et al., 2003; Taheri et al., 2002; O'Shea et al., 2003).  Furthermore, the role of 
apelin in regulating fluid homeostasis is discussed. The central administration of 
apelin to rats was associated with a reduction (Reaux et al., 2001) as well as an 
increase in water consumption (Taheri et al., 2002). However, in APJ and apelin 
knock-out mice, water intake and urine electrolyte concentration were not different 
from wild type mice (Kuba et al., 2007).  
Apelin modulates the hypothalamic–pituitary-adrenal axis, which appears to 
play an important role in stress adaptation and in regulation of inflammation during 
septic shock through corticotrophin-relasing factor and vasopressin mediated 
pathway (Newson et al., 2009). 
Recently published data suggest that the peripherial administration of apelin 
does not affect food intake but decreases body weight in dose dependent manner 
due to direct action of apelin on white adipose tissue lipid metabolism (Higuchi et al., 
2007).  In a study of both human and mouse adipocytes and in mouse model of 
obesity apelin has been identified as a novel adipokin that is released from fat cells 
and is upregulated directly by insulin (Boucher et al., 2005). Other early studies 
revealed that apelin and leptin secreted by adipocytes have similar insulin–
regulatory properties, both agents have a negative feedback on insulin levels and 
action which is a novel adipoinsular axis (Heinonen et al., 2005). However, further 
investigations will determine their distinct roles in adipoinsular system. 
1.3.3. Vascular Effects of Apelin 
Apelin modulates the tone of blood vessels, which has the overall effect of 
lowering blood pressure without any change in heart rate (Lee et al., 2000). The 
apelin induced reduction in blood pressure is mediated through nitric-oxid 
dependent pathway (Tatemoto et al., 2001). Maguire et al. proved the endothelium-
dependent vasodilatator activity of apelin via prostanoid-dependent pathway and 
the removal of the endothelium revealed the direct vasoconstrictor effect of apelin 
in arteries and veins too (Maguire et al., 2009). Moreover, Charles and co-workers 
found a biphasic response in mean arterial pressure and cardiac output after 
intravenous administration of apelin-13. The initial fall of mean arterial pressure and 
cardiac output was followed by a subsequent rise and then a return to baseline over 
15 minutes (Charles et al., 2006). Furthermore, apelin may modulate central control 
of arterial pressure since intracerebroventricular injection of apelin-13 increases 
both arterial pressure and heart rate in conscious rats (Kagiyama et al., 2005). But in 
case of injection apelin 13 into the nucleus tractus  solitaries and rostral  
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ventromedullar medulla also reveals increases in arterial pressure (Seyedabadi et al., 
2002). Although the overall systemic effect of apelin appears to decrease mean 
arterial pressure, differences may exist among particular anatomical region. The 
pathophysiological significance of apelin induced vasodilatation is proved in different 
knockout animal models too, with the important finding that apelin provides 
compensatory vasorelaxation to counteract Ang II-mediated vasoconstriction (Ishida 
et al., 2004). 
1.3.4. Apelin and the Renin-Angiotensin System  
Apelin-APJ system has a high sequence homology to the AngII/AT1-R and both 
systems show significant similarity in tissue distribution and activation on the same 
biological processes suggesting a close relation to each others. Moreover, the 
recently described zinc metalloproteinase angiotensin converting enzyme 2 (ACE 2) 
is responsible for inactivating angiotensin I, II and apelin-36, apelin-13. ACE 2 is 
distributed mainly in cardiac and renal tissues and insensitive to the classical ACE 
inhibitors (Vickers et al., 2002; Burrell et al., 2004). 
Ishida et al provided further evidence to prove the interaction between 
apelin/APJ and AngII/AT1-R systems. APJ knock out mice were highly sensitive to low 
dose Ang II treatment in contrast to the wild-type mice suggesting that the lack of 
apelin signaling prevents a possible counter-regulatory effect of apelin to mediate 
the pressor effects of AngII. These findings were further supported by another 
experiment in which the blood pressures of APJ/AT1-R double knock out mice 
showed partial normalisation compared with AT1-R single knock out mice (Ishida et 
al., 2004).   
The relation between apelin/APJ and AngII/AT1-R was investigated by 
Iwanaga et al in experimental model of heart failure in rats. Beside decreased 
ejection fraction the apelin and APJ mRNA were markedly down-regulated and the 
treatment with angiotensin blocker resulted in clinical improvement and increased 
expression of apelin and APJ in rats with heart failure. These experimental data 
emphasize that the beneficial effect of modulating rennin-angiotensin system in 
heart failure may be, at least partially, due to the restoration of apelin signaling 
(Iwanaga et al., 2006). 
1.3.5. Apelin and Inoptropy 
Apelin has recently been found to be a potent inotropic agent in isolated rat 
heart preparations (Szokodi et al., 2002). Szokodi et al. found a dose-dependent 
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positive inotropic effect in vitro due to specific activation of its receptors in the 
heart, which was independent of the release of cathecholamines, other vasoactive 
peptides (endothelin, Ang II) or nitric oxide. They investigated the underlying 
intracellular mechanisms and suggested that activation of PLC and PKC were 
involved in the positive inotropic effect observed in the presence of apelin. On the 
other hand researchers have found contradictory results. Hosoya and Marsi 
suggested that the APJ receptor couples through inhibitory G-proteins, because 
pertussis toxin inhibits the actions of apelin (Hosoya et al., 2000; Masri et al., 2006). 
It has been demonstrated that the APJ receptor is localised at the T-tubules raising 
the possibility that tubular Ca2+ channels could be involved in the positive inotropic 
effect of apelin (Kleinz and Davenport, 2004).  This has not been supported by 
perforated patch-clamp experiments which have shown no evidence of modulation 
of Ca2+ flux through L-type Ca2+ channels following apelin administration (Szokodi et 
al., 2002).  Wang et al. reported a double effect of apelin on intracellular Ca2+ 
concentration such as systolic increase and diastolic decrease via PKC dependent 
mechanism.  Moreover they found that apelin enhanced the activity of NCX and 
SERCA but the underlying mechanism has still been unknown (Wang et al., 2008).    
While the positive inotropic effect of apelin in isolated heart preparations has 
been repeatedly demonstrated, its effect in vivo is more complicated. For instance, it 
has been observed that cardiac output does not increase following acute 
administration of apelin. However, it causes a reduction in left ventricular 
enddiastolic area and increases in left ventricular elastance. Therefore, the change in 
loading conditions after acute apelin administration together with changes in the 
visco-elastic properties of the ventricle may influence the net effect of apelin on 
cardiac output. Chronic administration of apelin (two-week continuous infusion) 
resulted in significant increase in the velocity of circumferential shortening and 
cardiac output. Importantly, these hearts have shown no evidence of left ventricular 
cellular hypertrophy, which is frequently seen after chronic administration of 
positive inotropic substances (Ashley et al., 2005). There are experimental evidences 
that apelin knock out mice develop severe impairment in cardiac contractility, which 
becomes evident at six months of age. These data indicate as well, that apelin is 
important mediator to maintan cardiovascular homeostasis (Kuba et al., 2007). 
Moreover, the results of Dai et al suggest that apelin exerts a more pronounced 
positive inotropic effect in failing myocardium compared to normal trabecular 
muscle (Dai et al., 2006). Furthermore, apelin was found to be a cardioprotective 
agent too. Jia and colleagues found, that apelin improved the function of the heart 
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which had previously been damaged by isoproterenol (Jia et al., 2006). In an other 
experiment Kleinz and co-workers observed a cardioprotective effect of apelin 
during ischemia reperfusion injury (Kleinz and Baxter, 2008; Jia et al., 2006). These 
complex effects of apelin may be important when it is considered as a therapeutic 
agent in heart failure. 
There are numerous experimental data suggesting the importance of the 
apelin-APJ system regulating myocardial contractility in vivo, the direct effects of 
apelin on cardiomyocyte contractility and the underlying intracellular signaling 
mechanisms are unknown. 
1.3.6. Role of the Apelin–APJ System in Heart Failure 
The apelin–APJ signaling pathway has also been identified recently as a 
potentially important mediator in the pathophysiology of chronic heart failure (Jia et 
al., 2006; Berry et al., 2004; Ashley et al., 2005). There is evidence that circulating 
plasma apelin levels are increase in patients in the early stage of heart failure 
compared with the healthy population, but in patients suffering from severe heart 
failure the plasma apelin levels are less than normal (Chen et al., 2003; Foldes et al., 
2003). This finding may suggest that the increase in circulating apelin may be a 
compensatory mechanism in the early stage of heart failure to improve cardiac 
contractility. This theory was proved by Iwanaga et al., who demonstrated that 
myocardial apelin and APJ mRNA level is initially preserved in compensated 
ventricular hypertrophy and only downregulated when animals developed heart 
failure(Iwanaga et al., 2006). Foldes and coworkers have assessed left ventricular 
apelin and APJ receptor mRNA levels by quantitative RT-PCR and they found that 
apelin mRNA levels were increased and the APJ receptor mRNA was downregulated 
in heart failure in idiopathic dilatative cardiomyopathy (Foldes et al., 2003). The 
patients with heart failure due to ischaemic heart disease did not show these 
phenomena, suggesting that the primary disease underlying heart failure may 
probably influence cardiac APJ expression. However, in patients with dilated 
cardiomyopathy APJ polymorphism was not found in greater frequency compared to 
normal healthy controls (Sarzani et al., 2007).  
While there is continuing debate regarding apelin and mechanisms of APJ 
downregulation in HF, important changes in the apelin-APJ receptor expression have 
been observed following left ventricle assist device insertion. Chen and colleagues 
have identified the APJ receptor as one of the most upregulated  genes following 
offloading with ventricle assist device (Chen et al., 2003).  
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These early studies suggest that the apelin APJ axis is an important biomarker 
of heart failure and its upregulation is favourable regarding left ventricular 
remodeling. Recently published data have revealed that this includes improvement 
in endothelial function and decrease in cardiac fibrosis mediated via apelin/APJ and 
Akt/eNOS pathways (Fukushima et al., 2010). The interactions of apelin-APJ system 
with other neurohormonal systems involved in the pathogenesis of heart failure are 
not yet fully understood, as much as the effects of these modifying therapies (ACE 
inhibitors, beta-blockers) on apelin concentration. 
1.3.7. Apelin and Arrhythmias   
Apelin has also been implicated in the pathophysiology of arrhythmias; Elinor 
et al. demonstrated that plasma apelin levels decrease in patients with lone atrial 
fibrillation (Ellinor et al., 2006).  In agreement with this, Kallergis et al. found that 
successfull cardioversion of long-lasting atrial fibrillation led to significant increase in 
plasma apelin levels (Kallergis et al., 2010). However the role of the APJ-apelin 
system in the regulation of electrophysiological parameters in the heart is still poorly 
understood. 
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1.4. The Role of Adrenomedullin in the Regulation of the Cardiovascular System  
In 1993  Kitamura et al. isolated a novel peptide called andrenomedullin (AM) 
and since that time several hundreds of papers have been published regarding the 
regulation of its secretion and the wide range of its actions (Kitamura et al., 1993a). 
Substantial evidences support the perception that AM is an important regulator of 
the cardiovascular system (Kitamura et al., 1993a; Hamid and Baxter, 2005; Szokodi 
and Ruskoaho, 2008). 
1.4.1. Characterization of the Adrenomedullin System 
Human AM consists of 52 amino acids with an intramolecular disulfide bridge 
forming a ring structure of six residues with an amidated tyrosine at C-terminus  
(Kitamura et al., 1993b). Due to moderate sequence homology with calcitonin, 
calcitonin gene-related peptide (CGRP) an amylin, AM has six substitutions and two 
deletions (Sakata et al., 1993). Human AM is synthesized as a 185-amino-acid 
precursor. The cleavage of 21-amino-acid signal peptide from N-terminus of this 
prepro-AM leads to formation of a 164-amino-acid prohormone (Kitamura et al., 
1993a; Kitamura et al., 1994). The prohormone is further cleaved to liberate a 20-
amino-acid proadrenomedullin N-terminal 20-peptide (PAMP), which has been found 
to elicit biological effects independent of those of AM (Kitamura et al., 1994). The 
remaining prohormone is finally cleaved between positions 93 and 94 as well as 148 
and 149, resulting in the formation of human AM (Kitamura et al., 1994). 
  Immunoreactive AM and AM mRNA were detected in numerous peripherial 
tissues (lung, heart, kidney, liver, intestine) as well as various regions of the central 
nervous system (Kitamura et al., 1994). The adrenal gland contains proportionally 
the largest quantity of AM, but substantial amounts were found in the cardiovascular 
system (Kitamura et al., 1994; Sakata et al., 1993). AM expression show close 
correlation with the degree of tissue vascularisation. Both endothelial cells and 
vascular smooth muscle cells synthesize and secret AM and it is  the major source of 
circulating AM in the plasma  (Sakata et al., 1993; Kitamura et al., 1993b; Kitamura et 
al., 1994).  AM is present in a variety of embryonic tissues, particularly in the heart 
and cardiac myocytes and even further nonmol/lyocytes were found to secret AM 
(Jougasaki et al., 1995).   Several factors may influence the secretion of AM such as 
inflammatory cytokines and vasoactive substances, mechanical stretching, hypoxia 
and oxidative stress (Chun et al., 1997; Yoshihara et al., 2002; Kawai et al., 2004; 
Nakamura et al., 2004) . 
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The characterisation of a specific AM receptor failed until in 1998 McLatchie 
et al described a family of receptor-activity modifying proteins (RAMPs) which are 
single transmembrane–domain proteins that are associated with the calcitonin 
receptor-like receptor (CLR) to direct its ligand binding specifity and affinity. 
Coexpression of RAMP1 with CLR results in a functional CGRP receptor, whereas 
association of CLR with RAMP2 or RAMP3 confers preferential AM binding 
(McLatchie et al., 1998). 
1.4.2. Biological Effects of Adrenomedullin 
As a consequence of a wide distribution of AM and its receptors, AM has a 
remarkable range of action, from potent vaso- and coronary dilatator effect  through 
regulating cellular growth and differentiation to modulating hormone secretion 
(Samson, 1999) (Szokodi and Ruskoaho, 2008). There are some non-cardiovascular 
effects of AM as well;    experimental data suggest that andrenomedullin inhibits 
ACTH release (Samson, 1999; Parkes and May, 1997) and aldosteron production 
(Yamaguchi et al., 1996). Several studies investigated the effect of AM on steroid 
secretion but the results were contradictory (Hinson et al., 2000). AM was found to 
be co-secreted with catecholamine in response to nicotine receptor stimulation; 
however, in vivo experiments did not support this data (Katoh et al., 1994; Masada 
et al., 1999). The renal effect of AM was studied widely. Evidence exist for a role of 
locally secreted AM in regulation of renal blood flow and tubular function but it is 
unlikely that circulating level of AM regulates renal function in physiological 
condition (Hinson et al., 2000). Furthermore, there are evidence to prove the role of 
AM in the pathophysiology of mesangial cell proliferation and matrix biology such as 
in protecting kidney glomeruli from inflammatory reactions (Chini et al., 1995; Chini 
et al., 1997). AM plays a role in glucose metabolism as well. AM attenuates and 
delays the insulin response to oral glucose challenge (Martinez et al., 1996). On other 
gastrointestinal effect of AM is to influence the gastrointestinal motor and secretory 
function. In the lung, AM inhibits bronchoconstriction induced by histamine or 
acetylcholine and additionally AM significantly prohibits alveolar macrophage release 
of neutrophil chemoattractants in response to lipopolysaccharide (Hinson et al., 
2000).   
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1.4.3. Vascular Effects of Adrenomedullin 
The most characteristic property of AM is an intensive and sustained 
hypotension in different species (Hinson et al., 2000; Chini et al., 1995; Chini et al., 
1997). Moreover AM results in dose-dependent decrease in blood pressure in 
pathological conditions such as hypertension and heart failure (Rademaker et al., 
1997; Shimokubo et al., 1996). The vasodilator effect of AM is mainly mediated 
through induction of NO release (Feng et al., 1994). In case of impaired NO 
production such as  hypoxic condition the vasodilatation is induced by 
prostaglandins (Yang et al., 1996), furthermore  AM also able to inhibit endothelin-1  
production, which may contribute to vasorelaxation (Kohno et al., 1995). AM may 
act as a physiological antagonist of endothelin-1 (Kinnunen et al., 2001).   
AM is indispensable for vascular morphogenesis during embryonic 
development and recent studies suggest that AM may be an important angiogenic 
factor in pathological conditions during adulthood (Nagaya et al., 2005; Ribatti et al., 
2007). Experimental data suggest that AM exerts its angiogenic effect through 
activation of Akt and ERK  independently of each other (Kim et al., 2003; Miyashita et 
al., 2003). On the other hand the effects of AM on proliferation of vascular smooth 
muscle cells are controversial. The migration of vascular smooth muscle cells into the 
intimal layer is the mechanism of intimal thickening consequently resulting in 
vascular remodeling. Some studies demonstrated antiproliferatory action (Kano et 
al., 1996) whereas later studies suggest that AM is a potent mitogenic factor in 
cultured rat vascular smooth muscle cells (Iwasaki et al., 1998). 
1.4.4. Adrenomedullin and Inotropy 
The effect of AM on myocardial contractility is controversial. 
Systemic administration of AM results in marked haemodynamic effect such as 
decreased peripheral resistance, consequently increased heart rate, cardiac output 
and stroke volume (He et al., 1995; Parkes and May, 1997). This finding rises the 
question whether AM has a direct effect on contractility? In isolated, perfused rat 
heart AM increased cardiac contractility and dilated coronary arteries (Szokodi et al., 
1996; Szokodi et al., 1998). AM has appeared to be among the most potent 
endogenous positive inoptropic substances since AM was active in the 
subnanomolar range infused into coronary arteries. Moreover, the AM–induced 
increase in developed tension was approximately 60% of the maximal inotropic 
response to the β-adrenergic agonist isoproterenol (Szokodi et al., 2002). In contrary 
to β-adrenergic agonist effect , AM increased the contraction force gradually with 
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mean time of 25-30 min to reach its maximum effect (Szokodi et al., 1998; Kinnunen 
et al., 2000). AM was reported to increase isometric tension in isolated rat papillary 
muscles (Ihara, 2000 Eu J Pharm), but other studies suggested a distinct effect of AM 
on cardiac contractility.  A dual inotropic effect was observed in isolated adult rat 
ventricular myocytes, AM produced an initial increase in cell shortening followed by 
a negative inotropic effect on prolonged incubation (Mittra et al., 2004; Mittra and 
Bourreau, 2006). Former studies demonstrated a negative inotropic effect of AM on 
isolated rabbit cardiomyocytes (Ikenouchi et al., 1997) and human ventricular 
myocytes (Mukherjee et al., 2002). Other studies failed to detect any effect of AM on 
cardiac contractility (Stangl et al., 2000; Saetrum et al., 2000). 
Number of studies suggesting that AM induce an increase in cAMP and this 
may be the major pathway of the signaling (Eguchi et al., 1994; Ishizaka et al., 1994; 
Shimekake et al., 1995; Chini et al., 1995; Sato et al., 1997), in spite of the evidence 
that AM enhances cardiac contractility via cAMP-independent mechanism (Szokodi 
et al., 1998). However, now it is clear that AM has direct effect on cardiac 
contractility, the underlying intracellular signaling mechanisms are still largely 
unknown.  
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2. Aims of the Study 
 To evaluate the direct effect of apelin on contractile function of isolated normal and 
failing ventricular cardiomyocytes   
 
 To characterize the intracellular signaling mechanism of apelin 
 
 To investigate the effects of apelin on electrophysiological properties of 
cardiomyocytes  
 
 To evaluate the intracellular signaling mechanism of the positive inotropic effect of 
adrenomedullin  
  
26 
 
3. Direct  Effects of Apelin on Cardiomyocyte Contractility and 
Electrophysiology 
3.1. Introduction  
Regulation of myocardial contractility by endogenous peptides is important in 
physiological and pathophysiological conditions and may be a crucial therapeutic 
target (Brutsaert, 2003). An autocrine or paracrine system which potentially 
regulates heart function is the recently discovered APJ receptor with its endogenous 
ligand apelin. Ex vivo studies using isolated perfused rat hearts have identified apelin 
as one of the most potent inotropic substances recognised so far (Szokodi et al., 
2002). Moreover, apelin was reported to increase left ventricular contractility in vivo 
following acute (Berry et al., 2004; Ashley et al., 2005) as well as chronic infusion in 
rodents (Ashley et al., 2005).  
The APJ receptor and apelin have been implicated in the pathophysiology of 
human heart failure by a number of studies which identify this system as an 
attractive target for therapy (Lee et al., 2006; Kleinz and Davenport, 2005). Plasma 
concentration of apelin has been shown to decrease in patients with congestive 
heart failure (Foldes et al., 2003; Chong et al., 2006; Chen et al., 2003) and long-term 
cardiac resynchronization therapy could restore plasma levels of the peptide (Francia 
et al., 2006). Moreover, it has been demonstrated that left ventricular unloading 
with mechanical ventricular support increases APJ mRNA levels in patients with heart 
failure (Chen et al., 2003). Apelin has also been implicated in the pathophysiology of 
arrhythmias. Ellinor et al. demonstrated that plasma apelin levels decreased in 
patients with lone atrial fibrillation (Ellinor et al., 2006). 
Despite recent advances in our understanding of the cardiovascular effects of 
the apelin-APJ system in vivo, the direct effects of apelin on cardiomyocyte 
contractility remains unknown. Therefore, the objective of the present study was to 
characterize the effects of apelin as well as the underlying signaling pathways, such 
as cytoplasmic [Ca2+] and pH regulation in vitro using isolated adult rat ventricular 
myocytes. Moreover, to test the potential pathophysiological significance of apelin, 
we assessed the effect of the peptide on contractility in cardiomyocytes isolated 
from rat hearts in which chronic heart failure had been induced by coronary artery 
ligation. Finally, we studied the cellular localization of APJ and the effects of apelin 
on intercellular communication in cultured monolayers of cardiomyocytes. 
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3.2. Materials and Methods  
3.2.1. Cell Isolation and Failing Heart Model 
All animal procedures were performed in accordance with the UK Animal 
(Scientific Procedures) Act 1986. Adult female Sprague Dawley rats, weighing 200 g 
(Harlan, UK) were used for this study. All animals were anaesthetized using 1-2% 
isoflurane in 100% oxygen for every procedure (excision of the heart, 
echocardiography, coronary artery ligation). 
Cardiomyocytes were isolated using standard enzymatic dissociation 
(Terracciano and MacLeod, 1997). Briefly, the heart was perfused on a Langendorff 
apparatus with oxygenated normal Tyrode solution at 37°C for 2 minutes. The heart 
was then perfused with low Ca2+ solution for 5 minutes, followed by a 9 minutes 
perfusion with solution containing collagenase/hyaluronidase (see solutions). After 
discarding both atria and the right ventricle, the left ventricle was cut into small 
pieces and shaken in collagenase/hyaluronidase solution for a further 5 minutes. 
Cardiomyocytes were dissociated using gentle trituration, filtered through a 300 μm 
mesh and re-suspended in enzyme solution at room temperature until use. 
Failing hearts were obtained 8 weeks after left coronary artery ligation. 
Briefly, the anaesthetized rats were intubated with a 16G plastic cannula and 
mechanically-ventilated (Harvard Apparatus, Kent, UK) at 2.5 ml tidal volume and 70 
breaths per minute. A left-sided thoracotomy at the fourth intercostal space 
followed by pericardiectomy provided access to the heart. The left coronary artery 
was identified and permanently ligated at the level of the left atrial appendage using 
a 6-0 suture to cause myocardial infarction and subsequent heart failure. The 
diagnosis of heart failure was based on ejection fraction measured by using a 
15 MHz probe on an Acuson Sequoia™ 256 system (Siemens Medical Systems, 
Germany). Transthoracic echocardiography was performed to obtain parasternal 
short-axis views at the mid-papillary muscle level. Ejection fraction was calculated 
from the systolic and diastolic 2-dimensional cross-sectional left ventricular areas, 
and ejection fraction less than 30% was taken as heart failure. Cardiomyocytes were 
isolated from the viable left ventricle of these hearts as above. 
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3.2.2. Measurement of Cardiomyocyte Contraction 
Isolated cardiomyocytes were superfused with Krebs solution at 37°C and 
field-stimulated at 1Hz in a bath on the stage of an Olympus inverted microscope.  
Cell images were acquired with a ×60 objective at 240 frames per second and the 
sarcomere pattern was digitalized and analysed using Ionwizard™ software (Ionoptix 
Corp, CA, USA). Sarcomere shortening was measured in real time using a fast Fourier 
transformation of the cardiomyocyte striation pattern into a frequency power 
spectrum, as described previously (Delbridge 1997 J.Mol.Cell. Card.) 
3.2.3. Intracellular [Ca
2+
] Measurements 
Intracellular [Ca2+] was monitored using two different [Ca2+]-sensitive 
fluorescence indicators. In initial experiments cardiomyocytes were loaded with 
indo-1 AM (Invitrogen, UK) and studied whilst being superfused with Krebs solution 
and field-stimulated, as above. Indo-1 excitation was at 385 nm, and fluorescence 
emissions at 405 nm and 485 nm were acquired. After subtracting background 
fluorescence levels, F405/485 was calculated and used as a measure of [Ca2+]i. 
F405/485 transients were analysed using Ionwizard™ software.   
In another series of experiments cardiomyocyte [Ca2+] was studied using fluo-
4 AM (Invitrogen, UK). [Ca2+]i was calculated from fluorescence using the equation: 
 
 
 
Where F is fluorescence, Fo is background fluorescence, kd = 1160 nm and [Ca
2+]rest = 
100 nm as previously reported (Huser et al., 1998). 
For analysis of contractions and [Ca2+] transients, 10-15 events were averaged 
with reference to the field-stimulation signal. Peak amplitude and time-to-peak 
(Tpeak) were calculated from the field-stimulation signal baseline, and decay times 
(T50 and T90) were calculated from Tpeak. For the fluo-4 data the decay times (tau) 
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were calculated by fitting the data to a mono-exponential decay curve using 
pClamp™ software (Version 9.0. Axon Instruments, USA). 
3.2.4. Intracellular pH Measurements and Na
+
/H
+
 Exchanger Activity 
For measurement of intracellular pH (pHi) cardiomyocytes were loaded with 
10 µM 5-(and-6)-Carboxy-SNARF-1 AM (Invitrogen, UK) and superfused with Normal 
Tyrode solution at 37°C. Fluorescence excitation was at 480 nm. Data were 
expressed as the ratio of the emission wavelengths at 580 nm and 640 nm 
(F580/640).  
To monitor NHE activity, the NH4Cl pre-pulse method was used (Boyarsky et 
al., 1988). Briefly, the cells were perfused with normal Tyrode solution and two 5 
minute pulses of 15 mM NH4Cl were performed. Each pulse was followed by a 
recovery phase in normal Tyrode for 10 minutes, during which the pattern of 
recovery was recorded for analysis using pClamp™ software. The second NH4Cl pulse 
and subsequent recovery were performed either in normal Tyrode again (control) or 
in normal Tyrode containing apelin. The time constant (τ) of the monoexponential 
curve fitted on the acid extrusion phase was normalized to the τ following the first 
NH4Cl pulse.  The acid extrusion rate in these conditions was taken as an index of 
NHE activity. 
3.2.5. Immunocytochemistry 
Isolated cardiomyocytes were plated onto laminin-coated slides in culture 
medium. 10 μm thick cryosections of adult rat hearts were mounted onto polylysine 
coated slides. Isolated cardiomyocytes and cryosections were fixed with acetone at 
−20°C, washed with phosphate buffered saline, and incubated with primary 
antibodies (2 hours, room temperature). Two different antibodies raised against 
peptides from 2 separate regions of the receptor were used to confirm the labelling 
patterns observed, one to the C-terminal (rabbit anti-APJ Apelin receptor IgG, 
Phoenix Pharmaceuticals Inc., CA, US, dilution 1:100) and one to a cytoplasmic loop 
(rabbit anti-APJ, affinity purified antiserum, Neuromics, MS, US, dilution 1:1000).  
Slides were washed with PBS, incubated with anti-rabbit IgG conjugated to 
AlexaFlor596 (Invitrogen, UK) for 1 hour, washed again with phosphate buffered 
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saline and nuclei counterstained with DAPI (Invitrogen, UK) prior to mounting. 
Images were recorded using a Leica TCS SP confocal microscope. 
3.2.6. Cultured Neonatal Rat Cardiomyocytes 
Ventricles from 3 days old Sprague-Dawley rats were dissociated, cut into 
small pieces, resuspended in collagenase/pancreatine solution and shaken at 37oC (5 
cycles, 15-25 minutes each). Fetal bovine serum was added to the mixture to 
inactivate enzymes and cardiomyocytes were rinsed in Fetal bovine serum. 
Cardiomyocytes were then filtered and plated in complete medium (10% horse 
serum, 5% foetal calf serum (Sigma, UK)) in Petri dishes and incubated for 45 
minutes to enable fibroblasts to adhere and be removed. After assessing the viability 
using 0.4% trypan blue solution (Sigma, UK) neonatal cardiomyocytes were plated on 
multi-electrode array (MEA; Multi Channel Systems, Reutlingen, Germany) plates in 
1 ml neonatal rat medium at a density of 0.5 × 106 cells per plate, and cultured at 
37°C. Neonatal rat medium was replaced every 24 hours and cardiomyocytes were 
grown to form a confluent monolayer. 
3.2.7. Multi-electrode Array  
A multi-electrode array setup (Multi Channel Systems, Reutlingen, Germany) 
was used to monitor the origin and spread of electrical activity in confluent neonatal 
cardiomyocyte monolayers, as described previously (Meiry et al., 2001). 
Spontaneous electrical activity, conduction velocity and properties of the field 
potentials were recorded.  The raw data collected were filtered using a Savitzky-
Golay filter, and differentiated digitally to determine the local activation time at each 
electrode using the Matlab™ interface (v7.0.1, Mathworks Inc, Germany) and custom 
software created by U. Egert (MEA-Tools, version 2.8, University of Freiburg, 
Germany). An activation map/isochronal map was constructed by interpolating the 
local activation time values for the sites between the electrodes and extrapolating 
the local activation time values for the four corners of the MEA matrix and were 
plotted using the Matlab™ standard two-dimensional tools. 
The conduction velocity was calculated using the peripheral method, which 
utilizes the mean local activation time at each row of peripheral electrodes.  Using 
the assumption of an uniform conduction pattern, the local activation times for each 
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row were averaged.  The distance travelled along each external row is seven times 
the distance between two neighbouring electrodes, and using this information, the 
conduction velocity was calculated (Meiry et al., 2001). The length and shape of the 
field potential, a first derivative of the action potential, was analyzed by Clampfit™ 
software (Axon Instruments, USA).  
3.2.8. Solutions 
Normal Tyrode solution (in mmol/l): 
NaCl 140; KCl 6; glucose 10; MgCl2 1; CaCl2 1; N-2-hydroxyethylpiperazine-N'-2-
ethansulphonic acid (HEPES) 10; pH 7.4.  
Low [Ca
2+
] solution (in mmol/l): NaCl 120; KCl 5.4; CaCl2 0.045; MgSO4 5; Na
+-
pyruvate 5; glucose 20; taurine 20; HEPES 10; nitrilotriacetic acid 5; pH 6.96.  
Enzyme solution (in mmol/l): 
NaCl 120; KCl 5.4; CaCl2 0.2; MgSO4 5; Na
+-pyruvate 5; glucose 20; taurine 20; 
HEPES 10; pH 7.4.  
Collagenase/hyaluronidase solution: 
Enzyme solution with 1 mg/ml type-2 collagenase (280 u/mg, Worthington 
Biochemical, USA) and 0.6 mg/ml hyaluronidase (999 u/mg, Sigma, UK).  
Krebs solution (in mmol/l): 
NaCl 120; KCl  4.7; MgSO4·7H20 0.94; KH2PO4 1.22; NaHCO3 25, glucose 11.54.  
Neonatal rat medium (NRM): 
400 ml Dulbecco’s Modified Eagle’s Medium (DMEM, GIBCO, UK), 100 ml 199 
medium (HEPES modification), 60 ml 10% heat inactivated Horse Serum (Sigma), 
27.5 ml 5% heat inactivated Foetal Bovine Serum (FBS), 13.5 ml 1M HEPES, and 6 ml 
penicillin/streptomycin.  
Drugs 
The Apelin 16-isoform was used in these experiments (Phoenix Pharmaceuticals Inc., 
CA, US). 
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3.2.9. Statistical Analysis 
To assess statistical differences a one-way ANOVA with Tukey post hoc test or 
Bonferroni post hoc test analyses or paired t-tests were performed where 
appropriate. Results are expressed as mean ± standard error of the mean (n = 
number). P < 0.05 was interpreted as being statistically significant. 
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3.3 Results 
3.3.1. Cellular Localization of the APJ Receptor 
Confocal immunofluorescence microscopic imaging confirmed the presence 
of APJ receptor-like immunoreactivity in isolated adult ventricular myocytes and in 
heart tissue (Kleinz et al., 2005). APJ receptor-like immunoreactivity was detected in 
a transversal striated distribution associated with T-tubules (Fig. 2) and in the 
intercalated disc area (Fig. 2A, B, D and E). 
3.3.2. Effect of Apelin on Cardiomyocyte Contractility 
In isolated perfused rat hearts, apelin has been shown to induce maximal 
positive inotropic effect at concentrations of 1 nmol/l and 10 nmol/l (Szokodi et al., 
2002).  As shown in Figure 3, superfusion with 1 nmol/l and 10 nmol/l apelin 
increased sarcomere shortening of isolated adult ventricular myocytes, reaching a 
maximum after approximately 1 minute of superfusion (AP t1). This effect was 
transient, it lasted 1-2 minutes and sarcomere shortening returned and remained at 
control levels for the rest of apelin superfusion (AP t2) (Fig. 3). The maximal 
increases in sarcomere shortening in response to 1 nmol/l apelin (136±13 % (14), 
P<0.001) and 10 nmol/l apelin (138±14 % (14), P<0.05) at AP t1 are presented in 
Figure 3B. At the end of the experiments isoproterenol (30 nmol/l) application 
invariably induced a robust increase in sarcomere shortening (approximately 250 %) 
suggesting a maintained contractile reserve (Fig. 3). 
3.3.3. Effect of Apelin on Contractility in Failing Cardiomyocytes 
Subsequently, we studied the effect of apelin on sarcomere shortening in 
isolated cardiomyocytes from a rat model of chronic post-ischaemic heart failure. 
The sarcomere shortening of the failing myocytes in control conditions was 
significantly smaller compared to normal myocytes (Δ0.121±0.03 µm (24) p<0.001). 
As shown in Figure 3 C,D, apelin induced a transient increase in sarcomere 
shortening in failing cardiomyocytes (1 nmol/l apelin: 117±8.3% (12); 10 nmol/l 
apelin: 116±7.7% (12) p<0.05). Notably, the maximal responses to apelin in normal 
and failing cardiomyocytes did not differ significantly. 
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Figure 2. Confocal images showing the localization of the APJ receptor (green label) in 
isolated cardiac myocytes (A, B, C) and sections of heart tissue (D, E, F). Nuclei are shown in 
red. Two different antibodies gave the same labeling pattern of the T-tubules and at the 
intercalated disc, one to a C-terminal region (A, D), and the other to a cytoplasmic loop 
region (B, E). No labeling was observed in the secondary antibody controls (C, F). Bar 
markers A, B, C, = 25 µm, D, F,E = 50 µm.  
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Figure 3. Effect of apelin on sarcomere shortening of normal isolated cardiomyocyte. (3A) 
and failing isolated cardiomyocyte (3C) at the different time point; baseline, AP t1 (1 minute 
in apelin,) AP t2 (after 8 minutes in apelin) and iso 30 nmol/l of isoproterenol).  
Graph 3B shows a significant increase in sarcomere shortening of normal and graph 
3D of failing cardiomyocytes at both concentrations of apelin (1 nmol/l and 10 nmol/l l) after 
1 minute ( ** p>0.001, * p>0.05). Failing myocytes showed a similar behaviour to normal 
myocytes. No statistical difference could be detected at AP t2, nor in normal or failing 
cardiomyocytes.   
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3.3.4. Signaling Mechanisms of Apelin in Cardiomyocytes 
To investigate the mechanisms underlying the effect of apelin on contractility, 
cytoplasmic [Ca2+], the major intracellular mediator of contraction, was monitored 
using [Ca2+]-sensitive fluorescent indicators. Initially we performed experiments 
using the ratiometric indicator indo-1. No effect of apelin could be observed either 
on the amplitude or time course of [Ca2+] transients with both concentrations of 
apelin (1 nmol/l apelin: AP t1: 98.2±19 %, AP t2: 91.4±25 % (5) P>0.05; 10 nmol/l 
apelin: AP t1: 97.8±16%: AP t2: 89.6±28% (10) P>0.05). Isoproterenol, used as 
positive control, elicited a strong increase in [Ca2+] transient amplitude. To exclude 
the possibility that changes in cytoplasmic [Ca2+] were within the noise levels of indo-
1 acquisition, we repeated the experiments with fluo-4 AM, which had a better 
signal-to-noise ratio. The results from these experiments are described in figure 4. 
There was no difference in the amplitude of [Ca2+] transients upon application of 
apelin, it only increased in the presence of isoproterenol (Fig. 4A). There was no 
difference in the time course of the [Ca2+] transients (Fig. 4B and 4C; [Ca2+] transient 
amplitude in control %, 1 nmol/l apelin: AP t1: 93.79±2 % (15); 10 nmol/l apelin: AP 
t1: 94.47±3 %( 14)) after 1 or 8 minutes of apelin superfusion.  
To assess whether apelin affects intracellular pH and sarcolemmal NHE 
activity in isolated cadiomyocytes we monitored intracellular pH using the pH-
sensitive fluorescent indicator carboxy-SNARF-1 and we assessed the acid-extrusion 
ability of the NHE with the NH4Cl pre-pulse technique as previously described 
(Boyarsky Am J Physiol1998). Superfusion with 10 nmol/l apelin significantly 
decreased SNARF-1 fluorescence ratio suggesting an increase in the intracellular pH 
((control: 3.01±0.1 ratio units (11); 10 nmol/l apelin: 2.64±0.1 ratio units (11); 
p<0.01)) (Fig. 5A, 5B). As for contractility, this effect was transitory and SNARF-1 
fluorescence returned to control values after a few minutes. To assess the acid 
extrusion ability of NHE, 15 mM NH4Cl in NT solution was applied for 5 minutes 
followed by wash out with NT for 10 minutes. Once the SNARF-1 signal returned to 
baseline, 1 nmol/l or 10 nmol/l apelin was added to the superfusing solution and the 
NH4Cl prepulse was repeated (Fig. 5C). Apelin at both concentrations increased the 
speed of acid extrusion compared with control, suggesting an enhanced activity of 
NHE (Fig. 5D). 
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Figure 4. The effect of apelin on [Ca
2+] 
 transients measured by fluo-4 AM in normal 
cardiomyocytes (A). Apelin does not influence either the fluo-4 AM fluorescence 
amplitude (B) or the decay time (C). The nodrugl cells were superfused with normal 
Tyrode during the whole experiment even at the time point called isoproterenol  
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Figure 5. Changes in intracellular pH in the presence of 10 nmol/l apelin (A).  There 
was a significant increase in intracellular pH at both concentrations of apelin; the 
data are expressed in % of control values (B). A typical example of the change of NHE 
exchanger in normal cardiomyocytes superfused with 10 nmol/l apelin is shown in C. 
The acid-extrusion phase represents the activity of NHE exchanger and it was 
increased at both concentrations of apelin (D); the graph shows decay time as % of 
control (r.U=ratio unit)  
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3.3.5. Effect of Apelin on Intercellular Communication 
We subsequently assessed the electrophysiological properties of apelin in 
monolayers of cultured neonatal rat cardiomyocytes using multi electrode arrays. 
Recording of field potentials from spontaneously beating cultures revealed that 
apelin significantly increased conduction velocity (control: 18.34±1.4 cm/s; apelin: 
24.1±2.2 cm/s (5) (P<0.05), Fig. 6A) and decreased field potential duration (apelin 1 
nmol/l: 0.05±0.005 s (13); apelin 10 nmol/l: 0.048±0.005 s (15) P<0.05; Fig 6B). 
Isochronal maps showed reversible modifications in the patterns of activation (Fig. 
6C). Movies of the 3D reconstructed activation of the monolayer are available as a 
data supplement on the homepage to the original paper [Farkasfalvi et al.,BBRC, 357, 
889-895, 2007]. File Normal Tyrode_3D.avi shows a typical activation pattern under 
control conditions. Apelin changed the direction of activation in monolayer cultured 
cardiomyocytes (file apelin_3D.avi) and this effect was reversible upon wash out.  
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Figure 6. In cultured neonatal cardiomyocytes conduction velocity (CV)  increased (A) 
and field potential duration decreased with 10 nmol/l apelin (B). The isochronal map 
was constructed from local activation times (C); on the left the neonatal cultured 
cardiomyocytes were superfused with normal Tyrode and on the right with 1 
nmol/lol/l apelin. Apelin changed the direction of activation in monolayer cultured 
cardiomyocytes and this effect was reversible upon wash out.  
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3.4 . Conclusion  
APJ receptor-like immunoreactivity was detected in a transversely striated 
distribution associated with T-tubules as described previously and in the intercalated 
disc area, which is a novel finding.  
In isolated perfused heart model apelin increased sarcomere shortening of 
isolated adult ventricular myocytes, but it’s effect on isolated myocytes were 
transient and lasted 1-2 minutes, sarcomere shortening returned and remained at 
control levels for the rest of apelin superfusion. Apelin induced a transient increase 
in sarcomere shortening in failing cardiomyocytes too.  Notably, the maximal 
responses to apelin in normal and failing cardiomyocytes did not differ significantly. 
As the underlying signaling mechanism no changes in [Ca2+] transients were 
established but an increase in the intracellular pH and activity of NHE proved that 
apelin may increase the myofilament sensitivity to Ca 2+. 
This was the first attempt to establish the effect of apelin on 
electrophysiological properties. Apelin significantly increased conduction velocity 
and decreased field potential duration in spontaneously beating neonatal myocyte 
cultures and isochronal maps showed reversible modifications in the patterns of 
activation as well.  
  
42 
 
4. Adrenomedullin Regulates Cardiac Contractility via Extracellular Signal-
Regulated Protein Kinase-Dependent Mechanisms  
4.1. Introduction 
Mitogen-activated protein kinase (MAPK) superfamily represents an 
evolutionarily conserved signal transduction system that occupies a central position 
in the regulation of cell growth, proliferation, differentiation, apoptosis, and 
transformation in all eukaryotic cells (Widmann et al., 1999). Extracellular signal-
regulated kinases ERK1 and ERK2 (commonly referred to as ERK1/2) are members of 
the MAPK family. ERK1/2 signaling cascade is initiated in cardiac myocytes by 
activation of GPCRs, receptor tyrosine kinases, and by stress stimuli (Bueno and 
Molkentin, 2002; Wang, 2007). Accumulating data suggest that activation of the 
ERK1/2 signaling constitutes an essential adaptive mechanism int he myocardium, 
wherby it promotes cardiac myocyte survival in response to number of pathologic 
insults including ischemia-reperfusion injury (Lips et al., 2004) and long-term 
pressure overload  (Purcell et al., 2007). Although the ERK1/2 pathway has been 
implicated in various pathological conditions, its exact physiological role in the heart 
is not yet understood.  
AM with its cognate GPCR is widely expressed in the cardiovascular system 
and is emerging as an important regulator of cardiovascular homeostasis. AM, as an 
autocrine/paracrine factor, may protect the heart from pathological stress, e.g., AM 
inhibits maladaptive ventricular remodeling via reducing cardiomyocyte 
hypertrophy, apoptosis, and fibrosis (Ishimitsu et al., 2006). Moreover, AM is among 
the most  potent stimulators of cardiac contractility. Although it has been 
demonstrated that the peptide acts independently of the classical adenylylcyclase-
cAMP- PKA pathway (Szokodi et al., 1996; Szokodi et al., 1998), the precise 
underlying signaling mechanisms are not known. Previous studies have shown that 
AM increases ERK1/2 phosphorylation in various cell types including vascular smooth 
muscle cells (Iwasaki et al., 1998) and endothelial cells (Kim et al., 2003). In the 
present study, we tested wheather ERK1/2 signaling is activated by AM in the heart, 
and if so, whether it is involved in the inotropic response to AM. 
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4.2. Materials and Methods  
4.2.1. Materials 
Drugs used were AM (Phoenix Europe GmbH, Karlsruhe, Germany); AG1478 
and U0126 (Merck Chemicals Ltd., Nottingham, UK); zoniporide (generously supplied 
by Dr Ross Tracey, Pfizer Global Research and Development, Groton, Conn). AM was 
dissolved in distilled water; AG1478, U0126, and zoniporide were dissolved in 
dimethyl sulfoxide. The final concentration of each solvent was <0.003%. The 
addition of an appropriate concentration of each solvent caused no significant 
change in haemodynamic variables. 
4.2.2. Isolated Perfused Rat Heart Preparation 
 All protocols were reviewed and approved by the Animal Use and Care 
Committee of the University of Oulu and University of Pecs. Male 7-week-old 
Sprague-Dawley rats from the Center for Experimental Animals at the University of 
Oulu were used. Rats were decapitated and hearts were quickly removed and 
arranged for retrograde perfusion by the Langendorff technique as described 
previously (Szokodi et al., 1998; Szokodi et al., 2002; Szokodi et al., 2008; Kinnunen 
et al., 2000). The hearts were perfused with a modified Krebs-Henseleit bicarbonate 
buffer (see chapter 3.2.8.), pH 7.40, equilibrated with 95% O2-5% CO2 at 37°C. Hearts 
were perfused at a constant flow rate of 5.5 mL/min with a peristaltic pump 
(Minipuls 3, model 312). Heart rate was maintained constant (302±1 beats/min) by 
atrial pacing using a Grass stimulator (model S88, 11 V, 0.5 ms). Contractile force 
(apicobasal displacement) was obtained by connecting a force displacement 
transducer (Grass Instruments, FT03) to the apex of the heart at an initial preload 
stretch of 2 g. Perfusion pressure reflecting coronary vascular resistance was 
measured by a pressure transducer (model MP-15, Micron Instruments, Los Angeles, 
Calif) situated on a side arm of the aortic cannula. 
4.2.3. Experimental Design 
A 40-minute equilibration period and a 5-minute control period were 
followed by addition of various drugs to the perfusate for 30 minutes. The 
concentrations of U0126 (1.5 μmol/L), AG1478 (1 μmol/L), and zoniporide (1 μmol/L) 
were selected because these concentrations have been demonstrated to suppress 
ERK1/2 (Tenhunen et al., 2004; Szokodi et al., 2008), epidermal growth factor 
receptor (EGFR) tyrosine kinase activity (Thomas et al., 2002) (Szokodi et al., 2008) 
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and inhibit Na+/H+ exchanger 1 (NHE1) (Knight et al., 2001; Szokodi et al., 2002; 
Szokodi et al., 2008), respectively. In the final stage of the experiments, the left 
ventricles were frozen in liquid nitrogen and stored at –80 oC until assayed. 
4.2.4. Immunoblot Analysis 
Westernblotting was performed as described previously (Szokodi et al., 
1998). Left ventricular tissue was homogenized in lysis buffer containing of 20 
mmol/L Tris, (pH 7.5), 10 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 
supplemented with 1 mmol/L β-glycerophosphate, 2 mmol/L dithiothreitol (DTT), 1 
mmol/L Na3VO4, 10 μg/mL leupeptin, 10 μg/mL aprotinin, 2 μg/mL pepstatin, 2 
mmol/L benzamidine, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF) and 20 
mmol/L NaF. Total protein samples (30 μg) were loaded onto SDS-PAGE and 
transferred to nitrocellulose membranes. The membranes were blocked in 5% 
nonfat milk and incubated with indicated primary antibody overnight. Protein levels 
were detected using enhanced chemiluminescence. For a second staining, the 
membranes were stripped for 30 minutes at 60 °C in stripping buffer (62.5 mmol/L 
Tris (pH 6.8), 2% SDS, and 100 mmol/L β-mercaptoethanol). The antibodies used 
were anti-phospho-ERK1/2 and anti-ERK1/2 (Cell Signaling Technology Inc., Hitchin, 
Hertfordshire, UK). 
4.2.5. Statistical Analysis 
Results are presented as mean±SEM. Two-way repeated-measures ANOVA was used 
to evaluate the statistical significance of differences among groups for cardiac 
contractility. When significant differences were detected for the treatment-by-time 
interactions, a Bonferroni post hoc test was used for specific comparisons. All other 
parameters were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. 
Differences were considered statistically significant at the level of P<0.05. 
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4.3. Results 
4.3.1. Extracellular Signal-Regulated Kinase1/2 and Adrenomedullin-Induced 
Positive Inotropic Effect 
 To define the role of ERK1/2 in the cardiac effects of AM, we determined the 
impact of AM stimulation on the activation of these kinases. Western analysis 
revealed that infusion of AM (1 nmol/l) for 30 minutes significantly increased left 
ventricular phospho-ERK1/2 levels (Figure 7A) in the rat heart preparation. To 
examine whether activation of ERK1/2 contributes to the positive inotropic action of 
AM, we assessed the effect of U0126, which is a potent specific inhibitor of MEK1/2, 
the upstream regulator of ERK (Tenhunen et al., 2004; Szokodi et al., 2008). 
Administration of U0126 (1.5 μmol/l) markedly reduced the levels of phospho-
ERK1/2 both in the control and AM-stimulated hearts (Figure 7A). Infusing U0126 in 
combination with AM, the AM-induced inotropic effect decreased significantly, the 
maximal reduction being 40% (P<0.01; Figure 7B). Infusion of U0126 alone had no 
effect on contractile force (P=NS, Figure 7B). 
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Figure 7. ERK1/2 signaling is required for AM-mediated increase in contractility. A, 
Western blot analysis for ERK1/2 phosphorylation in left ventricular tissue samples. In 
isolated rat hearts, infusion of AM (1 nmol/l) for 30 minutes increased phospho-
ERK1/2 levels and U0126 (1.5 μmol/l), a MEK1/2 inhibitor, abolished AM-induced 
ERK1/2 phosphorylation. B, U0126 significantly attenuated AM-enhanced 
contractility. DT indicates developed tension. Results are expressed as a percent 
change versus baseline values. Data were analyzed by 2-way repeated-measures 
ANOVA followed by multiple comparisons with the Bonferroni post hoc test and are 
reported as mean±SEM (n=4-6 for each group). *P<0.01 and †P<0.001 vs control and 
U0126; ‡P<0.01 vs AM. 
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4.3.2. Upstream Activators of Extracellular Signal-Regulated Kinase1/2: Role of 
Epidermal Growth Factor Receptors 
 In cultured rat ventricular myocytes, agonist-stimulated ERK1/2 
phosphorylation can occur via transactivation of EGFR (Thomas et al., 2002). To 
define the importance of EGFRs in ERK1/2 activation in the adult rat heart, we used a 
specific EGFR tyrosine kinase inhibitor AG1478 (Szokodi et al., 2008; Thomas et al., 
2002). AG1478 (1 μmol/L) significantly reduced AM-induced increase in phospho-
ERK1/2 levels (Figure 8A). Moreover, in the presence of AG1478 the inotropic 
response to AM was significantly suppressed, the maximal reduction being 45% 
(P<0.001; Figure 8B). Infusion of AG1478 alone had no effect on developed tension 
(P=NS, Figure 8B). 
 
4.3.3. Downstream Targets of Extracellular Signal-Regulated Kinase1/2: Role of 
Na
+
/H
+
 Exchanger  
The ERK1/2 pathway has been identified as the main regulator of NHE-1 
phosphorylation in cardiac myocytes (Moor and Fliegel, 1999). To assess the 
contribution of NHE-1 to the effect of AM, we used zoniporide, a potent and 
selective inhibitor of NHE-1 (Knight et al., 2001; Szokodi et al., 2002; Szokodi et al., 
2008). Infusion of zoniporide (1 μmol/L) alone had no effect on contractile force 
(P=NS; Figure 9). When given together with AM, zoniporide significantly attenuated 
the AM-induced positive inotropic effect, the maximal reduction being 46% 
(P<0.001; Figure 9).  
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Figure 8. EGFR transactivation contributes to AM-mediated increase in contractility. 
A, Western blot analysis shows that AG1478 (1 μmol/l), an EGFR tyrosine kinase 
inhibitor, reduced AM-induced increases in ERK1/2 phosphorylation. B, AG1478 
reduced AM-induced increase in contractility. Data are mean±SEM (n=4-6 for each 
group). *P<0.01 and †P<0.001 vs control and AG1478; ‡P<0.001 vs AM. 
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Figure 9. NHE1 is involved in the inotropic response to AM. Zoniporide (1 μmol/l), a 
NHE1 inhibitor, attenuated AM-induced increase in contractility. Data are mean±SEM 
(n=4-6 for each group). *P<0.01 and †P<0.001 vs control and Zoniporide; ‡P<0.001 vs 
AM. 
 
4.4. Conclusion 
Our data are the first to demonstrate that AM increases cardiac contractility 
via activation of ERK1/2 in the intact adult rat heart. Moreover, our results show that 
EGFR acts as the upstream regulator and NHE-1 as the downstream effector of 
ERK1/2 in AM signaling. Identification of novel signaling pathways that promote 
cardiomyocyte survival while improving contractile function may offer an attractive 
approach of treating patients with heart failure. Therefore, further studies are 
required to test the hypothesis that activation of MEK1/2–ERK1/2 signaling, 
possessing such beneficial effects, can eventually rescue the failing heart. 
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5. Discussion 
5.1. Direct Effect of Apelin on Cardiomyocyte Contractility and Electrophysiological 
Properties 
The cellular mechanisms underlying the ex vivo (Szokodi et al., 2002) and in 
vivo effects of apelin on left ventricular function (Berry et al., 2004; Ashley et al., 
2005) required further investigation. The present study provides the first direct 
evidence for a positive inotropic effect of apelin in adult ventricular myocytes. Our 
results suggest that the positive inotropic effect of apelin is due to stimulation of the 
sarcolemmal NHE, leading to intracellular alkalinization and, possibly, increased 
myofilament sensitivity to Ca2+. In contrast to previous studies in intact hearts 
(Szokodi et al., 2002; Berry et al., 2004; Ashley et al., 2005) where apelin induced a 
sustained increase in contractility, our investigation highlights the fact that apelin 
induced a transient increase in contractility in cardiomyocytes, suggesting that 
additional mechanisms are present in the whole tissue. Furthermore, our data define 
a previously unrecognized role of apelin in the regulation of cardiac conduction as 
apelin increases conduction velocity in monolayers of cultured neonatal rat 
cardiomyocytes. 
5.1.1. Apelin and Cardiomyocyte Contractility 
Apelin induced a transient increase in sarcomere shortening in adult rat 
cardiomyocytes, which was not accompanied by changes in cytoplasmic Ca2+ 
transients. Charo et al. confirmed our findings in apelin-APJ double knock out mice 
model(Charo et al., 2009). Since the NHE has been indicated as a target for apelin 
(Hosoya et al., 2000) and changes in intracellular pH strongly shift the [Ca2+]-
contractility curve in cardiac tissue (Kohmoto et al., 1990), we investigated the 
effects of apelin on intracellular pH and on NHE activity. We found that apelin 
increased pH and NHE activity in cardiomyocytes. Moreover, confocal 
immunofluorescence microscopic imaging showed that APJ is localized in the 
intercalated disc regions, which accommodate NHE as well (Snabaitis et al., 2006). 
Taking previous studies into consideration demonstrating that the apelin-induced 
increase in contractility was significantly attenuated by a specific inhibitor of NHE in 
isolated perfused rat hearts (Szokodi et al., 2002), the present data indicate that 
intracellular alkalinization with subsequent sensitization of cardiac myofilaments to 
[Ca2+] can be involved in the inotropic effect of apelin. 
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Dai et al showed that at higher concentrations of apelin right ventricular 
failing trabeculae increased the developed tension compared with non-failing 
trabeculae (Dai et al., 2006). They proposed that apelin had a predominant role in 
regulating cardiac contractility in the failing myocardium. We investigated the 
hypothesis that the increased apelin-induced inotropy in heart failure is brought 
about by augmented effects on cardiac myocytes. However, in our study, despite a 
transient increase in sarcomere shortening, there was no additional effect of apelin 
on failing compared with normal cardiomyocytes. 
Numerous studies have demonstrated the effect of exogenous apelin in the 
regulation of contractility, but only the recently published data reveal the 
importance of the endogenous apelin-APJ pathway. Apelin and APJ knock out mice 
were examined. Under basal condition both of them manifested modest decrements 
in contractile function while with exercise stress both mutant lines demonstrated 
consistent and striking decrease in exercise capacity (Charo et al., 2009).    
An intriguing finding of this study is the lack of a sustained effect of apelin on 
cell contractility. This is in obvious contrast with previous observations in intact 
hearts, where apelin possessed a slowly developing but sustained inotropic response 
(Szokodi et al., 2002; Berry et al., 2004; Ashley et al., 2005). In isolated isovolumic rat 
hearts apelin enhanced preload-induced increase in dP/dtmax only at higher levels of 
left ventricular end-diastolic pressure, suggesting that the peptide augments cardiac 
contractility along the upper part of the ascending limb of the Starling relation 
(Szokodi et al., 2002). If mechanical load is crucial in determining the effects of 
apelin, isolated unloaded cardiomyocytes would have a limited inotropic response 
upon application of apelin. Another explanation may be the increased sodium 
current due to the apelin infusion. Chamberland et al. demonstrated that apelin 
increases cardiac sodium current whithin 5 minutes of perfusion and reached steady 
state at 20 minutes (Chamberland et al., 2010). Thus; these results may suggest that 
increased NHE activity and enhanced cardiac sodium current underlie the positive 
inotropic response to apelin.  
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Figure 10. Putative signaling mechanisms of apelin in the heart. Stimulation of APJ by 
apelin evokes phosphorylation of PKC leading to activation of NHE, NCX and Na
+
 
channels. The positive inotropic effect of apelin is the result of sensitization of cardiac 
myofilaments to Ca
2+
 due to intracellular alkalosis and increased Ca
2+
 influx through 
the NCX operating in reverse mode (Chamberland et al., 2010; Szokodi et al., 2002). 
5.1.2. Apelin and Electrical Conduction 
Our results demonstrate that apelin caused an increase in the frequency of 
spontaneous activation, conduction velocity and a decrease of the field potential 
duration in monolayers of cultured neonatal cardiomyocytes. The underlying 
mechanism, explained by Chamberland et al in2009, is due to the increase in cardiac 
sodium current by apelin, which accelerates the initial depolarization of ventricular 
action potential resulting in increased excitability of cardiac cells (Chamberland et 
al., 2010). The localization of APJ receptor in the intercalated disc region, the cellular 
structure involved in the electric coupling between cardiomyocytes, further supports 
the hypothesis that apelin may play an important role in intercellular 
communication. The effects of apelin on electrophysiological properties of cardiac 
tissue may explain the changes in APJ-apelin system observed in chronic arrhythmias 
and after cardiac resynchronization therapy (Ellinor et al., 2006). The specific role of 
apelin in regulating cardiac electrophysiology needs to be investigated further. 
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5.1.3. Summary  
 We have provided the first evidence that apelin has direct effects on the 
propagation of action potential and contractility in normal cardiomyocytes. The 
latter, however, possibly mediated by action on the NHE, is transitory and apelin 
may require other mediators and/or mechanical loading to exert its lasting inotropic 
action. 
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5.2 The Role of Adrenomedullin in the Regulation of Cardiac Contractility  
Considerable evidence suggests that AM acts an autocrine or paracrine factor 
in regulating cardiac contractility. AM has been considered to be among the most 
potent endogenous positive inotropic agent, however the literature data are 
controversial and the underlying intracellular signaling mechanisms are still 
discussed.  
5.2.1. Signaling Mechanism of Adrenomedullin 
 Experimental data suggests that activation of the adenylyl cyclase-cAMP 
system, which is one of the major pathways for regulation of cardiac contractility, 
may also mediate the cardiac effect of AM.  High doses of AM augmented cardiac 
contractility in association with increased cAMP formation and inhibition of PKA 
could abolish the positive inotropic effect of the peptide in rat papillary muscles 
(Ihara et al., 2000). However, other experimental data indicate that cAMP is not the 
major second messenger of the inotropic effect of AM at physiologically more 
relevant concentrations. First, AM failed to to increase left ventricular cAMP content 
in perfused rat hearts. Second, PKA inhibition did not reduce the positive inotropic 
effect of AM. Finally, the response to AM could not be enhanced in the presence of 
phosphodiesterase inhibitor. In contrast of the cAMP mediated pathway the 
importance of PKC activation in the positive inotropic effect of AM was mentioned 
by Szokodi et al. (Szokodi et al., 1998). Activated PKC can phosphorylate a wide 
spectrum of cellular proteins, including L-type Ca2+ channel resulting in increased 
Ca2+ influx.  Taken together the literature data, the signaling pathway of positive 
inotropic effect of AM is only partially understood and it indicates further research 
to find alternative signaling mechanisms.   
5.2.2. Alternative Intracellular Signal Transduction Pathways  
Growing body of evidence suggest that activation of the MEK1/2–ERK1/2 
pathway protects the heart from various pathological insults. ERK1/2 signaling has 
been reported to afford cardioprotection in vivo against ischemia–reperfusion injury 
by reducing myocyte apoptosis (Lips et al., 2004). Recently, the requirement of 
ERK1/2 signaling in stress adaptation has been directly addressed using Erk1-/- and 
Erk2
+/- mice, as well as transgenic mice with inducible expression of an ERK1/2–
inactivating phosphatase in the heart (dual-specificity phosphatase 6). Although the 
hypertrophic response is not affected in these models after long-term pressure 
overload, mice with selective ablation of cardiac ERK1/2 signaling show greater 
55 
 
propensity towards heart failure through increased myocyte apoptosis (Purcell et al., 
2007). Moreover, genetic deletion of type 5 adenylyl cyclase results in the 
upregulation of the MEK1/2–ERK1/2 pathway, which in turn protects the heart from 
aging-induced cardiomyopathy in terms of preservation of left ventricular function 
and resistance to myocyte apoptosis (Yan et al., 2007). Though systolic function is 
clearly affected in these transgenic models, it has only been established recently that 
ERK1/2 can directly modulate cardiac contractility. Our recent studies have provided 
evidence for the functional importance of ERK1/2 signaling in the acute regulation of 
cardiac contractility by showing that endothelin-1 increases contractile force via the 
ERK1/2  pathway (Szokodi et al., 1998). In the present study, the GPCR agonist AM 
produced a significant increase in LV phospho-ERK1/2 levels, and pharmacological 
inhibition of ERK1/2 activation markedly attenuated the AM–induced increase in 
contractile force in the intact rat heart. Previously we have demonstrated that the 
positive inotropic response to AM is independent of the adenylyl cyclase–cAMP–PKA 
pathway (Szokodi et al., 1998), and our current data indicate that ERK1/2 signaling 
serves as a key mediator of the inotropic effect of AM. While prolonged stimulation 
of the adenylyl cyclase–cAMP–PKA cascade leads to serious adverse cardiac effects, 
activation of the MEK1/2–ERK1/2 pathway may enhance both cardiac contractility 
and overall stress resistance of the myocardium. 
Transactivation of EGFR has been established as a major mechanism for GPCR 
agonists to activate ERK1/2 (Thomas et al., 2002). Stimulation of GPCRs induces 
metalloproteinase-mediated ectodomain shedding of membrane-anchored 
proheparin-binding EGF. Soluble heparin-binding EGF then binds to and activates 
EGFR, triggering MEK1/2–ERK1/2 phosphorylation (Wetzker and Bohmer, 2003). 
Notably, pharmacological inhibition of EGFR by erlotinib provokes dilated 
cardiomyopathy with reduced cardiac function in the face of chronic β-adrenergic 
stimulation (Noma et al., 2007). Recently, we have found that transactivation of 
EGFR is a critical step for endothelin-1 to enhance cardiac contractility via the 
MEK1/2–ERK1/2 cascade (Szokodi et al., 2008). In line with these observations, 
inhibition of EGFR transactivation by the specific EGFR tyrosine kinase inhibitor 
AG1478 was accompanied by significant attenuation of AM–induced increase in 
phospho-ERK1/2 levels as well as the inotropic response to AM. Thus, the present 
data highlight the importance of EGFR in the regulation of myocardial contractility 
acting as an upstream signaling molecule modulating MEK1/2–ERK1/2 cascade.  
Activated ERK1/2 can phosphorylate various cellular proteins including the 
sarcolemmal NHE1 (Moor and Fliegel, 1999). In the present study, zoniporide, a 
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highly selective inhibitor of NHE1, attenuated the inotropic response to AM 
suggesting that NHE-1 may serve as a downstream effector of ERK1/2 signaling. 
Stimulation of NHE1 can lead to intracellular alkalinization and sensitization of 
cardiac myofilaments to intracellular Ca2+. On the other hand, NHE-1-mediated 
accumulation of intracellular Na+ can indirectly promote a rise in intracellular levels 
of Ca2+ via reverse mode NCX exchanger (Kentish, 1999). The finding that ≈50% of 
the AM–induced positive inotropic effect remained unaffected after inhibition of the 
EGFR–ERK1/2–NHE-1 pathway indicates the existence of additional signaling 
mechanisms such as PKC (Szokodi et al., 1998) or phosphoinositide 3-kinase (Kim et 
al., 2003). 
 
 
 
Figure 11. Putative signaling mechanisms activated by adrenomedullin. ERK1/2 
signaling serves as a key mediator of the inotropic effect of AM. EGFR acts as the 
upstream regulator and NHE-1 as the downstream effector of ERK1/2 in AM 
signaling. 
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5.2.3. Summary 
Our data are the first to demonstrate that AM increases cardiac contractility 
via activation of ERK1/2 in the intact adult rat heart. Moreover, our results show that 
EGFR acts as the upstream regulator and NHE-1 as the downstream effector of 
ERK1/2 in AM signaling. Identification of novel signaling pathways that promote 
cardiomyocyte survival while improving contractile function may offer an attractive 
approach of treating patients with heart failure. On the other hand, MEK1/2–ERK1/2 
signaling is activated in most human tumors, and clinical trials of specific MEK1/2 
inhibitors are underway (Sebolt-Leopold and Herrera, 2004). Our results raise the 
possibility that cancer therapies that target the MEK1/2–ERK1/2 pathway might 
cause adverse cardiac side effects. 
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6. Novel Findings 
• Apelin increases sarcomere shortening transiently in normal and failing isolated adult 
ventricular myocytes.  
 
• Apelin has no effect on the amplitude or time course of [Ca2+] transients. 
 
• Apelin increases myofilament sensitivity to Ca2+ due to the stimulation of 
sarcolemmal NHE. 
 
• APJ receptor is localised in the intercalated disc region. 
 
• Apelin influences the electrophysiological properties in monolayer of cultured 
neonatal rat cardiomyocytes. 
 
• AM increases cardiac contractility via activation of ERK1/2 in the intact adult rat 
heart. 
 
• EGFR acts as the upstream regulator and NHE1 as the downstream effector of 
ERK1/2 in AM signaling. 
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